共 253 条
[1]
Kanis JA(2019)Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women Calcif Tissue Int 104 235-238
[2]
Cooper C(2016)Epidemiology of fractures in the United Kingdom 1988–2012: variation with age, sex, geography, ethnicity and socioeconomic status Bone 87 19-26
[3]
Rizzoli R(2013)Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US Appl Health Econ Health Policy 11 485-497
[4]
Reginster JY(2019)Epidemiological survey of osteoporosis in China and “Healthy Bones” special action results released Chinese J Osteoporos Bone Miner Res 12 317-318
[5]
Curtis EM(2003)Osteoclast differentiation and activation Nature 423 337-342
[6]
van der Velde R(2018)Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients Ann Pharmacother 52 1031-1041
[7]
Moon RJ(2012)Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada J Med Econ 15 3-14
[8]
van den Bergh JPW(2015)Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain Clinicoecon Outcomes Res 7 105-117
[9]
Geusens P(2015)Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service J Clin Densitom 18 150-156
[10]
de Vries F(2017)Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan Osteoporos Int 28 1733-1744